Plastic Surgeon, Otolaryngologist

Video profile
Accepting new patients
Ent Specialists
25500 Meadowbrook Rd
Ste 220
Novi, MI 48375
Locations and availability (6)

Education ?

Ear Research Foundation (2006) *
* This information was reported to Vitals by the doctor or doctor's office.

Awards & Distinctions ?

Patients' Choice Award (2011, 2013)
Compassionate Doctor Recognition (2013)
American Osteopathic College of Otolaryngology - Head & Neck Surgery
American Academy of Otolaryngic Allergy
American Academy of Otolaryngology: Head and Neck Surgery
American Osteopathic Association
Michigan Osteopathic Association
American Osteo College of Otolaryngology-head & Neck Surgery

Affiliations ?

Dr. Farrugia is affiliated with 11 hospitals.

Hospital Affilations



  • Botsford Hospital *
    28050 Grand River Ave, Farmington Hills, MI 48336
    • Currently 4 of 4 crosses
    Top 25%
  • Saint Joseph Mercy Saline Hospital
    400 W Russell St, Saline, MI 48176
    • Currently 4 of 4 crosses
    Top 25%
  • Saint Joseph Mercy Livingston Hospital
    620 Byron Rd, Howell, MI 48843
    • Currently 4 of 4 crosses
    Top 25%
  • Providence Hospital and Medical Center *
    16001 W 9 Mile Rd, Southfield, MI 48075
    • Currently 4 of 4 crosses
    Top 25%
  • Detroit Receiving Hospital & University Health Center
    4201 Saint Antoine St, Detroit, MI 48201
    • Currently 3 of 4 crosses
    Top 50%
  • Saint Joseph Mercy Hospital
    505 E Huron St, Ann Arbor, MI 48104
    • Currently 3 of 4 crosses
    Top 50%
  • St John Detroit Riverview Hospital
    7733 E Jefferson Ave, Detroit, MI 48214
    • Currently 3 of 4 crosses
    Top 50%
  • Huron Valley-Sinai Hospital *
    1 William Carls Dr, Commerce Township, MI 48382
    • Currently 2 of 4 crosses
  • Providence Park Hospital
    47601 Grand River Ave, Novi, MI 48374
  • Sinai-Grace Hospital
    6071 W Outer Dr, Detroit, MI 48235
  • St. Joseph Mercy Hospital-Ann Arbor
  • Publications & Research

    Dr. Farrugia has contributed to 3 publications.
    Title Osteonecrosis of the Mandible or Maxilla Associated with the Use of New Generation Bisphosphonates.
    Date March 2006
    Journal The Laryngoscope

    OBJECTIVE: The use of bisphosphonates is well established for the treatment of patients with metastatic bone disease, osteoporosis, and Paget's disease. Osteonecrosis of the mandible or maxilla associated with the use of bisphosphonates is a newly described entity never before discussed in the otolaryngology literature. In this paper, we review a series of patients diagnosed with osteonecrosis, all treated with new generation bisphosphonates. Our objective is to inform and educate others, particularly otolaryngologists/head and neck surgeons, about this drug induced entity, a condition that should be recognized early to avoid potential devastating consequences. STUDY DESIGN: Retrospective chart review of a series of patients from a tertiary referral center. METHODS: Pathology reports of specimens submitted from either the mandible or maxilla were reviewed from the previous 12 months. Any patient diagnosed with osteonecrosis without evidence of metastatic disease at that site was included; those with a previous history of radiation therapy were excluded. Each patient's medical history and profile were reviewed. RESULTS: Twenty-three patients were identified with osteonecrosis of the mandible or maxilla. All of these were associated with the use of new generation bisphosphonates: zolendronate (Zometa, Novartis), pamidronate (Aredia, Novartis), and alendronate (Fosamax, Merck). Eighteen patients with known bone metastases had been treated with the intravenous form, whereas five patients with either osteoporosis or Paget's disease were using oral therapy. Patients typically presented with a nonhealing lesion, often times the result of previous dental intervention. Although the majority of these patients were treated with conservative surgical debridement, we present a case requiring a near total maxillectomy. CONCLUSIONS: Drug induced osteonecrosis of the mandible or maxilla has been recently recognized as a sequelae of treatment with the new generation of bisphosphonates. Most patients can be treated with conservative surgical debridement and cessation of bisphosphonate therapy, whereas a few may require radical surgical intervention. Other recommendations include regimented prophylactic care with an assessment of dental status before the administration of bisphosphonates, avoidance of dental procedures, and close monitoring of oral hygiene.

    Title The Canadian Experience with Advance Treatment Directives.
    Date September 1995
    Journal Humane Medicine
    Title Successes and Complications of the Baha System.
    Journal Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

    OBJECTIVE:: To determine the incidence and type of complications, as well as patient satisfaction, associated with the Baha system. STUDY DESIGN:: Retrospective case review. SETTING:: The Silverstein Institute, Sarasota, Florida, and the Columbia University Medical Center, New York, New York. PATIENTS:: Patients with conductive/mixed hearing loss and single-sided deafness implanted with the Baha system between June 1998 and December 2007. INTERVENTION:: Implantation with the Baha system. MAIN OUTCOME MEASURE:: Incidence and type of complications associated with Baha implantation and patient satisfaction as measured by a questionnaire administered on site or by telephone. RESULTS:: In our series of 218 patients (223 ears), there were no major complications. Of these patients, 4.5% required revision surgery for soft tissue complications and 1.3% needed revision for failure of osseointegration. Eight percent (8%) required local care and resolved within 2 to 3 weeks of treatment. Five percent (5%) required in office procedures. One hundred six (106) patients satisfactorily completed the survey questionnaire. Ninety-two percent (92%) reported using the device regularly and 77% were happy with the device. On average, patients reported using the device 10.1 h/d, 5.6 d/wk. CONCLUSION:: The Baha system is safe and effective in the rehabilitation of patients with conductive or mixed hearing losses and with single-sided deafness. The high success rate, patient satisfaction rate, and predictable auditory outcome place the Baha among the leading choices for auditory rehabilitation.

    Similar doctors nearby

    Dr. Brandon Musgrave

    Detroit, MI


    40 years experience
    Clinton Township, MI

    Dr. Johnny Mao

    5 years experience
    Detroit, MI

    Dr. Anil Gupta

    17 years experience
    Royal Oak, MI

    Dr. Paul Finkel

    38 years experience
    Madison Heights, MI

    Dr. Sidney Beck

    42 years experience
    Sterling Heights, MI
    Search All Similar Doctors